KemPharm (KMPH) Tops Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
KemPharm, Inc. Reports First Quarter 2016 Results
May 12, 2016 4:06 PM EDT
Recent Clinical Development & Regulatory Highlights:
Introduced Apadaz as the proprietary name for KP201/APAPFDA Advisory Committees voted 16 to 4 in support of Apadaz approval; voted 18 to 2 against inclusion of abuse deterrent labelingGranted Fast Track designation for, and received clearance from FDA to initiate human clinical trials, of KP511, KemPharms prodrug of hydromorphone
Recent Corporate and Financial Highlights:
... More
